Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
System-State: Number of processed items 22.266 Notifications successully processed since Inception
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US24661P8077
State: 09.01.2025 | 12PM
Do you already know our new terminal view? Click here.
FIGI: BBG000BY2VF5
DCTH
Delcath Systems, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Medical Devices
NAME
Delcath Systems, Inc.
ISIN
US24661P8077
TICKER
DCTH
MIC
XNAS
REUTERS
DCTH.OQ
BLOOMBERG
DCTH US
Fri, 03.01.2025       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of an individual w...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Mon, 30.12.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which resulted in $16.3 million of funding. Approximately 6.6% of the warrants exercised were subject to ...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Mon, 02.12.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO™ in c...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Fri, 08.11.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter and Recent Business Highlights Total third quarter r...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Fri, 01.11.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following upcoming investor conferences: Stephens Biotechnology Virtual Fireside Chats Date: Wednesday, November 13, 2024 Fireside Chat Time: 9:30 a...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Fri, 25.10.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2024, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call Information To participate...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Thu, 17.10.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary revenue results for the third quarter of 2024, achieving $11.2 million, which included the recording of $10.0 million in U.S. revenue from the com...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Fri, 20.09.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted three equity awards, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of three indiv...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Mon, 16.09.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase 3 trial of HEPZATO KIT™ (melphalan/Hepatic Delivery System (HDS)) in patients with metastatic uveal melanoma (mUM). The data were presented by Dr. M...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Wed, 28.08.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024 at 11:00 a.m. Eastern Time at the Lott...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Wed, 28.08.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a clinical study in the journal Therapeutic Advances in Medical Oncology. The publication, entitled “Melanoma-specific survival of patients...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Tue, 27.08.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company specializing in the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective study by independent investigators in the Annals of Surgical Oncology. The study, titled “Hepatic and Overall Progression-Fre...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Mon, 26.08.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH) (“Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of an independent study conducted by investigators at the University Hospital of Leipzig, Germany, in the European Society for Medical Oncology journal o...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Tue, 20.08.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it will present data from its FOCUS Phase 3 study at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting, which convenes from September ...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink
Mon, 12.08.2024       Delcath Systems
US24661P8077

Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted one equity award, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of an individual ...
Read More
Delcath Systems
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.